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Summary 
Dyslipidemia is the risk factor of cardiovascular disease, but the 
relationship between the plasma triglyceride (TG) levels and 
total/cardiovascular mortality has not yet been analyzed in Slavs. 
The aim of our study was to analyze the association between the 
fasting TG levels and all-cause/cardiovascular mortality. We have 
examined 3,143 males and 3,650 females, aged 58.3±7.1 years. 
729 deaths (274 cardiovascular deaths) have been registered 
during up to 11.8 years of follow-up. Age-sex adjusted all-cause 
mortality was higher in individuals with TG values 3.01-4.00 
mmol/l (HR 1.37, 95 % CI 1.02-1.83, P=0.035) and over 4.00 
mmol/l (HR 1.66, 95 % CI 1.21-2.27, P=0.002) when compared 
with a reference group (TG 1.41-1.80 mmol/l). Elevated risk 
remains significant when adjusted for education, marital status 
and unemployment. When further adjusted for smoking, BMI and 
dyslipidemia interventions, HR for those in above 4.00 mmol/l 
group decreased (1.42, P=0.04). The results have been similar 
when cardiovascular mortality has been examined, however, 
results reached statistical significance only for the TG over 
4.0 mmol/l (P=0.028). Our results confirmed that enhanced 
plasma levels of plasma triglycerides are dose dependently 
associated with increased risk of all-cause mortality, however, 
it seems that individuals with TG values 1.8-3.0 mmol/l are not in 
higher risk of death.  
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Introduction 
 
There is wide range of risk factors associated with 
increased risk of cardiovascular disease and mortality 
(some of them summarized by Hopkins and Williams 
1981). Elevated levels of plasma lipids are listed among 
the seven major risk factors (together with smoking, 
obesity, hypertension, diabetes, low physical activity, and 
abundant alcohol intake) which are responsible for the 
majority of cases of cardiovascular and, more interestingly, 
all-cause mortality in industrialized countries. 
Despite decades of research, there are still many 
inconsistencies in estimation of risk values and we are not 
able to predict mortality and morbidity with reasonable 
accuracy. Interestingly, the importance of individual risk 
factors has not been examined, confirmed and verified in 
all geographic regions. This is particularly true for the 
former communist countries with Slavonic population. 
As suggested before, the distribution and the importance 
of some risk factors can differ not only between the 
ethnic groups (Kanjilal et al. 2008), but also between the 
geographic regions or countries (Petursson et al. 2012). 
These differences mostly reflect the different 
environmental conditions, environmental factors and 
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different genetic background of such populations. 
High plasma lipids, or dyslipidemia (DL) are at 
the top of considered risk factors. Dyslipidemia is based 
on the measurements of fasting plasma lipids although no 
clear and universal general definition is presented in 
guidelines (Ray et al. 2014). General recommendations 
usually do not use absolute values, but suggest “target 
values” for different types of individuals. Generally, 
values used for DL definition are plasma total cholesterol 
over 5.0 mmol/l, triglycerides over 1.8 mmol/l or HDL 
cholesterol below 1.0 mmol/l for males and below 
1.2 mmol/l for females (Soska et al. 2013).  
Definition based on plasma total cholesterol is 
still used despite the fact that there is increasing level of 
uncertainty about the mortality risks associated with 
elevated plasma levels of total cholesterol (for example 
Matsuzaki et al. 2002, Ravnskov 2009, Langsted et al. 
2011, Petursson et al. 2012, Tamosiunas et al. 2014, 
Hubacek 2015) and many studies show rather protective 
effect of slightly elevated plasma cholesterol, especially 
in elderly (over 50 or 55 years) individuals. Furthermore, 
recent Mendelian randomisation study argued against 
HDL-cholesterol being a causal risk factor of 
cardiovascular disease (Haase et al. 2012). Thus plasma 
triglycerides seem to remain last important factor, 
defining dyslipidemia, which should be taken into 
account (Miller et al. 2011, Kohli and Cannon 2012).  
In this paper we conducted an analysis to evaluate 
the role of plasma triglyceride levels as a risk factor for all-
cause and cardiovascular mortality in Central European 
Slavonic population from the Czech Republic.  
 
Methods 
 
The analysis has been performed on 6,793 
individuals with TG and mortality data (3,143 men and 
3,650 women, mean age 58.3±7.1 years at the time of the 
baseline examination) examined in the Health, Alcohol 
and Psychosocial factors In Eastern Europe (HAPIEE) 
study. Although the HAPIEE is an international study, 
only subjects from the Czech Republic (collected at six 
centers – Havirov/Karvina, Hradec Kralove, Jihlava, 
Kromeriz, Liberec and Usti nad Labem) have been 
included in this report. All individuals were self-reported 
Caucasians. The HAPIEE study was approved by ethics 
committees at University College London and Czech 
National Institute of Public Health. All participants gave 
informed consent. The protocol of the selection and 
examination was described in detail by Peasey et al. 
(2006) and by Hubacek et al. (2011, 2014).  
Deaths were obtained from the National death 
register. Follow up was between 8.6 and 11.8 years 
among those surviving till the end of study period; mean 
follow-up being 9.85 years. Plasma triglycerides were 
measured enzymatically in the Regional Lipid Reference 
Center, with a Roche COBAS MIRA autoanalyzer 
(https://usdiagnostics.roche.com/products/11877771216/
PARAM67/overlay.html).  
In order to assess the association between the 
plasma TG levels and all-cause mortality, fasting plasma 
TG was categorized into following groups: less than 
1.00 mmol/l; 1.01-1.40 mmol/l; 1.41-1.80 mmol/l;  
1.81-2.40 mmol/l; 2.41-3.00 mmol/l; 3.01-4.00 mmol/l, 
and over 4.01 mmol/l. 
Based on the recommendations used for the 
population-based MONICA study (Cifkova et al. 2010) 
a group of individuals with plasma TG values between 
1.41-1.80 mmol/l has been used as a reference category, 
with HR 1.00. 
Cox regression was used to investigate the 
association between TG and mortality. The estimated 
hazard ratios (HR) indicate the change in mortality 
between reference category and other categories of TG. 
The analysis has been conducted in several steps. Firstly, 
the association between TG and all-cause mortality has 
been adjusted for sex and age, as two major non-
modifiable factors affecting plasma TG values. 
Furthermore, the association was additionally adjusted for 
education, marital status, employment status (step 2), 
smoking status, body mass index (BMI, calculated as 
kg/m2) (step 3), past knowledge of high total cholesterol 
(including individuals treated for dyslipidemia 
pharmacologically and/or due to the life style 
interventions) (step 4). Finally, as plasma TG levels 
correlate with HDL-cholesterol levels, an additional 
adjustment has been performed for HDL-cholesterol in all 
steps of the analysis. 
The analysis was then repeated using CVD 
cause-specific mortality as further outcome of interest.  
Stata v.13 has been used for all statistical 
analyses (StataCorp, College Station, TX, USA). 
 
Results 
 
General characteristics of the examined 
individuals are summarized in Table 1. Mean fasting 
plasma TG were 2.15 mmol/l in males and 1.72 mmol/l in 
females. 
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During the follow up, 729 (10.7 % of analytical 
sample) have died. 274 deaths (4.0 % of all individuals, 
37.6 % of all deaths) were due to cardiovascular causes. 
 
 
Table 1. General characteristics of the examined individuals. 
 
N 6,793 
% of males 46.3 
Age (years)  58.3 ± 7.1 
TG levels (mmol/l) 1.92 ± 1.35 
Total cholesterol levels (mmol/l) 5.73 ± 1.05 
BMI (kg/m2)  27.5 ± 4.1 
Ever smokers prevalence (%) 56.2 
Diabetes prevalence (%) 11.3 
 
Values for continuous variables are given as mean ± SD. 
 
In general, similar to other populations, our 
results suggest the association between high plasma 
triglyceride levels and both all-cause mortality (Table 2) 
and cardiovascular mortality (Table 3). 
Table 2 shows the results for all-cause mortality. 
All-cause mortality was similar in subgroups from the 
lowest values of TG (below 1.00 mmol/l) to the subgroup 
with values between 2.41-3.00 mmol/l, and this fact was 
not influenced by further adjustments. Individuals with 
plasma TG values between 3.01-4.00 mmol/l and over 
4.00 mmol/l have elevated risk of mortality by 37 % 
(P=0.035) and 66 % (P=0.002), respectively, when age 
and sex adjusted. Further adjustment reduced this 
elevation and only those with TG levels above 
4.00 mmol/l had significantly higher risk of death in fully 
adjusted model.  
 
 
Table 2. HR (95 % CI) of all-cause mortality in different categories of plasma triglycerides. 
 
  Adjustment 
Triglycerides N total 
(N deaths) 
Age and sex Age, sex, education, 
marital status, 
employment status 
Age sex, education, 
marital status, 
employment status 
smoking, BMI 
Age sex, education, 
marital status, 
employment status 
smoking, BMI, past 
knowledge of high TG 
Below 1.00 1262 (131) 1.06 (0.81-1.37) 1.11 (0.85-1.44) 1.15 (0.88-1.51) 1.13 (0.86-1.48) 
1.01-1.40 1186 (103) 1.10 (0.87-1.38) 1.11 (0.88-1.41) 1.13 (0.89-1.44) 1.11 (0.87-1.42) 
1.41-1.80 1620 (162) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
1.81-2.40 1249 (140) 1.11 (0.88-1.41) 1.09 (0.85-1.39) 1.05 (0.82-1.34) 1.03 (0.81-1.32) 
2.41-3.00 629 (67) 1.01 (0.75-1.35) 0.98 (0.72-1.33) 0.87 (0.64-1.19) 0.84 (0.62-1.16) 
3.01-4.00 468 (69) 1.37 (1.02-1.83) 
P=0.035 
1.35 (1.00-1.82) 
P=0.049 
1.24 (0.91-1.68) 
P=0.166 
1.25 (0.92-1.69) 
P=0.160 
Above 4.01 379 (57) 1.66 (1.21-2.27) 
P=0.002 
1.58 (1.14-2.19) 
P=0.004 
1.40 (1.02-1.96) 
P=0.046 
1.42 (1.02-1.98) 
P=0.039 
 
Further adjustment for HDL-cholesterol levels did not change the results with one minor exception: fully adjusted model becomes  
non-significant at P=0.052. 
 
 
Similar trends have been observed for 
cardiovascular mortality (Table 3). Here, the risk of death 
after age and sex adjustment was 1.30 (n.s.) for those in 
3.01-4.00 mmol/l group and 1.66 (P=0.026) for those in 
4.00+ mmol/l group. While the magnitude of the effect 
was similar to all-cause mortality, majority of the results 
have been (borderline) non-significant due to lower 
number of cases and lower analytical power. 
 
 
Discussion 
 
In our study, we have shown that elevated 
plasma levels of triglycerides are associated with 
increased risk of both all-cause and, in some extent, 
cardiovascular mortality in Central European Slavonic 
population from the Czech Republic. In the case of  
all-cause mortality this finding was documented on crude 
data as well as after the adjustment for sex, age, 
education, marital status, smoking, BMI values and past 
S358   Pikhart et al.  Vol. 64 
 
 
respondent’s knowledge about high cholesterol levels 
including respondent being on dyslipidemic treatment or 
dietary intervention. It needs to be further mentioned that 
almost all individuals treated for dyslipidemia are on low 
prescribed doses (10-20 mg per day) of statins and 
triglyceride lowering effect of statins is not large – 
clinical trials reported TG lowering effect of statins to be 
between 10 and 20 %, and in general clinical praxis,  
5-10 % decrease is usually achieved. Our results 
underline the importance of the use of the plasma TG 
values for estimating risk of mortality in Central 
European Slavonic population. 
Results in our study are similar to those obtained 
in recently published large meta-analysis including more 
than 330,000 individuals (with 58,000 cases of all-cause 
mortality) from 61 studies (Liu et al. 2013). They have 
used TG between 1.01 and 1.65 mmol/l (90-149 mg/dl, 
respectively) as reference category, and reported relative 
risk for all-cause mortality being 1.09 and 1.20, 
respectively, in categories 1.65-2.24 mmol/l and over 
2.25 mmol/l. The analysis of cardiovascular mortality 
revealed similar results. Interestingly, there were no 
significant differences between ethnic groups and regions 
as European, American and Asia/Pacific regions have 
been compared. 
In contrast to the previously published studies 
and meta-analyses, we have detected higher borderline 
values as those increasing the risk. In Czechs, values 
higher than 3.0 mmol/l have been detected as risky, but 
the risk associated with these values is higher than in 
previously published studies. In five subgroups between 
“below 1 mmol/l” and “2.41-3.00 mmol/l”, there were no 
differences in risk of all-cause, or CVD mortality. Age 
and sex adjusted HRs have been between 0.87 and 1.12 in 
these categories, with no observed linear association. This 
shift could be explained by the fact, that considerable part 
of studies included in the meta-analysis have started in 
last millennium and different environmental exposures 
(such as consumed diet) could be expected.  
Some mechanisms of the association between 
plasma TG levels and increased morbidity and mortality 
have been previously discussed (Miller et al. 2011, Kohli 
and Cannon 2013, Kackov et al. 2013, Varbo et al. 2013, 
Borén et al. 2014). Generally, they focused on some 
distinct aspects of possible link rather than covering 
possible complexity of the association. One such possible 
explanation is, for example, the association between 
plasma triglycerides and higher oxidative stress/reactive 
oxygen species (ROS) as shown in animal models (Pérez-
Rodríguez et al. 2015) and in humans (Yubero-Serrano et 
al. 2013).  
Our study focused on all-cause mortality from 
several reasons. Firstly, general life expectancy is of 
major interest in general population. Secondly, the 
reduction of the incidence of one type of cause-specific 
mortality without increase in life expectancy would only 
mean redistribution in causes of death. Thirdly, the 
number of deaths related to specific diagnoses 
(cardiovascular, cancer and “other”) is still relatively low 
and analysis of cause-specific mortality has limited 
power.  
Finally, previous studies suggested, that the 
association between high plasma TG levels and mortality 
is similar for total and cardiovascular mortality (Liu et al. 
Table 3. HR (95 % CI) of cardiovascular mortality in different categories of plasma triglycerides. 
 
  Adjustment 
Triglycerides N total 
(N deaths) 
Age and sex Age sex, education, marital status, employment status 
smoking, BMI, past knowledge of high TG 
Below 1.00 1262 (48) 0.87 (0.59-1.29) 0.96 (0.64-1.45) 
1.01-1.40 1186 (32) 1.12 (0.81-1.55) 1.10 (0.78-1.56) 
1.41-1.80 1620 (63) 1.00 (ref) 1.00 (ref) 
1.81-2.40 1249 (49) 0.96 (0.67-1.36) 0.86 (0.59-1.24) 
2.41-3.00 629 (31) 0.94 (0.61-1.44) 0.73 (0.46-1.17) 
3.01-4.00 468 (29) 1.30 (0.85-1.98) 1.14 (0.73-1.79) 
Above 4.01 379 (22) 1.66 (1.06-2.61) 
P=0.028 
1.32 (0.81-2.14) 
 
 
Further adjustment for HDL-cholesterol levels virtually did not change the results. 
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2013). Other studies focusing on the role of triglycerides 
showed similar associations with other causes of disease. 
Borena et al. (2011) have demonstrated increased risk of 
different types of cancer in individuals with higher TG 
values. The relative risk associated with increased TG 
values was almost identical as in the case of 
cardiovascular mortality described by Liu et al. (2013). 
Similarly, the risk of kidney disease (Navaneethan et al. 
2012) has been associated with plasma TG values. 
Widely discussed, but with inconsistent results is also the 
association between plasma TG levels and suicides 
(Ainiyet and Rybakowski 2014, Baek et al. 2014, Chang 
et al. 2012). Elevated plasma triglycerides have also been 
shown to predict all-cause mortality in patients with 
type 2 diabetes mellitus (Miselli et al. 2014), and have 
also been risk for the development of acute pancreatitis 
(Lindkvist et al. 2012).  
Several strengths of our study should be 
mentioned. Firstly, it is based on the general population 
sample, thus the risk of selection bias is small. 
Furthermore, the relatively long follow-up in our study 
(over 9 years on average) reduces possibility of reverse 
causation (Szklo and Nieto 2006), and further exclusion 
of deaths in the first two years of the follow-up did not 
change the results significantly. Finally, the data for study 
individuals have been collected within the short time 
period and this fact minimizes the risk that some 
environmental changes during time of data collection 
influence these findings. 
We conclude that high levels of plasma 
triglycerides are associated with increased total mortality 
risk. This increased risk is associated with fasting plasma 
triglyceride levels over 3.0 mmol/l. This means that about 
15 % of the population at age over 50 years is under 
increased risk of death because of the higher plasma TG 
concentrations.  
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